Adverse event monitoring of antiretroviral drugs- A pharmacovigilance perspective

Rakshit Sehgal, M. C. Gupta, P. S. Ghalaut

Abstract


Objective: To monitor and evaluate adverse drug reactions (ADRs) to antiretroviral drugs in patients of HIV/AIDS by active and spontaneous/solicited ADR monitoring.

Methods: A prospective observational study to monitor ADRs was carried out over 12 months in 187 patients of HIV/AIDS taking antiretroviral treatment. The ADRs reported were evaluated for incidence, frequency, causality, severity, seriousness and preventability. Causality assessment was done using the WHO-UMC and Naranjo scale, seriousness was considered as per the ADR reporting form, severity and preventability assessment were done as per the Hartwig severity scale and the modified Schumock and Thornton criteria respectively.

Results: 103 patients (55.1%) reported at least one ADR and 108 ADR reports were collected. Mostly the ADRs came from the tenofovir + lamivudine + efavirenz regimen with efavirenz related to most number of ADRs (52.5%). Maximum ADRs belonged to the system organ class of neurological disorders (64.81%) followed by gastrointestinal (19.44%) and skin and appendages disorders (7.40%). Causality assessment by WHO-UMC scale revealed most of the reactions as ‘possible’ (99.2%) while Naranjo scale assessed most of them as ‘probable’ (69.8%). Most of the reactions (96.1%) were ‘mild’ in nature and no serious reactions were reported. Preventability assessment determined most reactions (94.6%) as ‘not preventable’.   

Conclusion: Antiretroviral drugs have a huge potential for causing ADRs specially neurological and gastrointestinal. Active pharmacovigilance is vital in recognizing such reactions to ensure timely management and optimal therapeutic outcomes.


Keywords


Antiretrovirals, Adverse Drug Reactions, Pharmacovigilance

Full Text:

PDF

References


Centers for disease control and prevention. About HIV/AIDS [Internet]. 2016. Available from: http://www.cdc.gov/hiv/basics/whatishiv.html

World Health Organization. HIV/AIDS Fact Sheet [Internet]. 2016 [updated 2016 July]. Available from: http://www.who.int/mediacentre/factsheets/fs360/en/

National AIDS Control Organization & National Institute of Medical Statistics, ICMR, Ministry of Health and Family Welfare, Government of India. India HIV estimations 2015: Technical Report. 2015. 27 p. Available from: http://www.naco.gov.in/upload/2015%20MSLNS/HSS/India%20HIV%20Estimations%202015.pdf

Flexner C. Antiretroviral Agents and Treatment of HIV infection. In: Brunton LL, Chabner BA, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 12thed. New York: McGraw Hill; 2011. p. 1623-63.

World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: Recommendations for a public health approach. WHO Press; 2013: 269. Available from: http://www.who.int/hiv/pub/guidelines/arv2013/download/en/

World Health Organization. The safety of medicines in public health programmes: Pharmacovigilance an essential tool. WHO Press; 2006. 60 p. Available from: http://www.who.int/medicines/areas/quality_safety/safety_efficacy/Pharmacovigilance_B.pdf

Lihite RJ, Lahkar M. An update on the Pharmacovigilance Programme of India. Front Pharmacol. 2015; 6:194.

Kalaiselvan V, Prasad T, Bisht A, Singh S, Singh GN. Adverse drug reactions reporting culture in Pharmacovigilance Programme of India. Indian J Med Res. 2014; 140:563–4.

IPC. Memorandum of Understanding (MoU) Signed between Indian Pharmacopoeia Commission (IPC) and National AIDS Control Organization (NACO) to set up pharmacovigilance systems to monitor the safety of antiretroviral (ARV) medicines. Available from: http://ipc.nic.in/writereaddata/mainlinkFile/File288.pdf

The Uppsala Monitoring Centre. The use of the WHO-UMC system for standardised case causality assessment [Internet]. Available from: http://who-umc.org/Graphics/24734.pdf

Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981 Aug; 30(2):239-45.

Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm. 1992 Sep; 49(9):2229–32.

Schumock GT, Thornton JP. Focusing on the preventability of adverse drug reactions. Hosp Pharm. 1992 Jun; 27(6):538.

Kumar A, Majhee L, Gari M. Causality, severity and preventability assessment of adverse drug reactions in patients received anti-retroviral therapy in a tertiary care hospital: A retrospective study. Natl J Physiol Pharm Pharmacol. 2016 Sep 1; doi: 10.5455/njppp.2017.7.0821922082016.

Rajesh R, Vidyasagar S, Varma DM, Guddattu V, Patel NR, Varghese M, et al. Evaluating the effects of combination antiretroviral therapy regimens and the development of adverse drug reactions in Indian human immunodeficiency virus positive patients. Saudi J Health Sci. 2014; 3(2):107-17.

Shet A, Antony J, Arumugam K, Dodderi SK, Rodrigues R, DeCosta A. Influence of Adverse Drug Reactions on Treatment Success: Prospective Cohort Analysis of HIV-Infected Individuals Initiating First-Line Antiretroviral Therapy in India. PLoS ONE. 2014 Mar; 9(3):e91028.

Reddy AVK, Lihite RJ, Lahkar M, Choudhury U, Baruah SK. A study on adverse drug reactions in HIV infected patients at a ART centre of tertiary care hospital in Guwahati, India. Asian J Pharm Clin Res. 2013; 6(2):102-4.

Sharma A, Vora R, Modi M, Sharma A, Marfatia Y. Adverse effects of antiretroviral treatment. Indian J Dermatol Venereol Leprol. 2008 May-Jun; 74(3):234-7.

Chen LF, Hoy J, Lewin SR. Ten years of highly active antiretroviral therapy for HIV infection. Med J Aust. 2007 Feb 5; 186(3):146–51.

Nagpal M, Tayal V, Kumar S, Gupta U. Adverse drug reactions to antiretroviral therapy in AIDS patients at a tertiary care hospital in India: A prospective observational study. Indian J Med Sci. 2010 Jun; 64(6):245-52.

Molina JM, Ferchal F, Rancinan C, Raffi F, Rozenbaum W, Sereni D, et al. Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus–infected patients. J Infect Dis 2000 Aug; 182(2):599–602.

Nelson MR, Katlama C, Montaner JS, Cooper DA, Gazzard B, Clotet B, et al. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS. 2007 Jun 19; 21(10):1273-81.

Fagot JP, Mockenhaupt M, Bouwes-Bavnick JN, Naldi L, Viboud C, Roujeau JC. Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. AIDS 2001 Sep 28; 15(14):1843-8.

Law WP, Dore GJ, Duncombe CJ, Mahanontharit A, Boyd MA, Ruxrungtham K, et al. Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT cohort, Thailand, 1996–2001. AIDS. 2003 Oct 17; 17(15):2191–9.

Jha AK, Gadgade A, Shenoy AK, Chowta MN, Ramapuram JT. Evaluation of adverse drug reactions in HIV positive patients in a tertiary care hospital. Perspect Clin Res. 2015 Jan-Mar; 6(1):34-8.




DOI: http://dx.doi.org/10.7439/ijpr.v7i3.3988

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM

Refbacks

  • There are currently no refbacks.




Copyright (c) 2017 International Journal of Pharmacological Research

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.